Immune signatures and systems biology of vaccines

Immunologic Signatures of Rejection

Volumn , Issue , 2011, Pages 141-167

  Buonaguro, F M ^b   Tornesello, M L ^b   Buonaguro, L ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NONE

Author keywords

Adaptive immunity; Adjuvants; APCs; Immune memory; Immunogenomics; Innate immunity; PAMPs; Proteomics; PRRs; Systems biology; TLRs; Vaccine

Indexed keywords

EID: 79958196954     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-7219-4_10     Document Type: Chapter

References (197)

1. Abbas AR, Baldwin D, Ma Y et al. (2005) Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data. Genes Immun 6:319-331.
2. Agrawal S, Agrawal A, Doughty B et al. (2003) Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol 171:4984-4989.
3. Ahmad-Nejad P, Hacker H, Rutz M et al. (2002) Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 32:1958-1968.
4. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783-801.
5. Alderson MR, Smith CA, Tough TW et al. (1994) Molecular and biological characterization of human 4-1BB and its ligand. Eur J Immunol 24:2219-2227.
6. Alexopoulou L, Holt AC, Medzhitov R et al. (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413:732-738.
7. Alexopoulou L, Thomas V, Schnare M et al. (2002) Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat Med 8:878-884.
8. Alizadeh AA and Staudt LM (2000) Genomic-scale gene expression profiling of normal and malignant immune cells. Curr Opin Immunol 12:219-225.
9. Allen A, Obaro S, Bojang K et al. (2003) Variation in Toll-like receptor 4 and susceptibility to group A meningococcal meningitis in Gambian children. Pediatr Infect Dis J 22:1018-1019.
10. Alvarez D, Vollmann EH, Von Andrian UH (2008) Mechanisms and consequences of dendritic cell migration. Immunity 29:325-342.
11. Andres PG, Howland KC, Nirula A et al. (2004) Distinct regions in the CD28 cytoplasmic domain are required for T helper type 2 differentiation. Nat Immunol 5:435-442.
12. Aricò E, Wang E, Tornesello ML et al. (2005) Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation. J Transl Med 3:45
13. Asahi-Ozaki Y, Itamura S, Ichinohe T et al. (2006) Intranasal administration of adjuvantcombined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes Infect 8:2706-2714.
14. Assudani D, Cho HI, De Vito N et al. (2008) In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res 68:9892-9899.
15. Bachmann MF, Zinkernagel RM, Oxenius A (1998) Immune responses in the absence of costimulation: viruses know the trick. J Immunol 161:5791-5794.
16. Bakal C, Linding R, Llense F et al. (2008) Phosphorylation networks regulating JNK activity in diverse genetic backgrounds. Science 322:453-456.
17. Baldridge JR and Crane RT (1999) Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 19:103-107.
18. Banchereau J and Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245-252.
19. Banchereau J, Klechevsky E, Schmitt N et al. (2009) Harnessing human dendritic cell subsets to design novel vaccines. Ann N Y Acad Sci 1174:24-32.
20. Banus S, Bottema RW, Siezen CL et al. (2007) Toll-like receptor 4 polymorphism associated with the response to whole-cell pertussis vaccination in children from the KOALA study. Clin Vaccine Immunol 14:1377-1380.
21. Belshe RB, Edwards KM, Vesikari T et al. (2007) Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 356:685-696.
22. Beltinger CP, White PS, Maris JM et al. (1996) Physical mapping and genomic structure of the human TNFR2 gene. Genomics 35:94-100.
23. Beutler B (2004) Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430:257-263.
24. Bhat NK, Thompson CB, Lindsten T et al. (1990) Reciprocal expression of human ETS1 and ETS2 genes during T-cell activation: regulatory role for the protooncogene ETS1. Proc Natl Acad Sci U S A 87:3723-3727.
25. Blumenthal SG, Aichele G, Wirth T et al. (1999) Regulation of the human interleukin-5 promoter by Ets transcription factors. Ets1 and Ets2, but not Elf-1, cooperate with GATA3 and HTLV-I Tax1. J Biol Chem 274:12910-12916.
26. Bochud PY, Bochud M, Telenti A et al. (2007a) Innate immunogenetics: a tool for exploring new frontiers of host defence. Lancet Infect Dis 7:531-542.
27. Bochud P Y, Hersberger M, Taffe P et al. (2007b) Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS 21:441-446.
28. Bowie A and O'Neill LA (2000) The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J Leukoc Biol 67:508-514.
29. Bowie AG and Unterholzner L (2008) Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol 8:911-922.
30. Brass AL, Dykxhoorn DM, Benita Y et al. (2008) Identification of host proteins required for HIV infection through a functional genomic screen. Science 319:921-926.
31. Brightbill HD, Libraty DH, Krutzik SR et al. (1999) Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 285:732-736.
32. Bulut Y, Faure E, Thomas L et al. (2001) Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. J Immunol 167:987-994.
33. Buonaguro L, Racioppi L, Tornesello ML et al. (2002) Induction of neutralizing antibodies and CTLs in Balb/c mice immunized with Virus-like Particles presenting a gp120 molecule from a HIV-1 isolate of clade A (HIV-VLPAs). Antiviral Res 54:189-201.
34. Buonaguro L, Visciano ML, Tornesello ML et al. (2005) Induction of systemic and mucosal crossclade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J Virol 79:7059-7067.
35. Buonaguro L, Tornesello ML, Tagliamonte M et al. (2006) Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J Virol 80:9134-9143.
36. Buonaguro L, Devito C, Tornesello ML et al. (2007) DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with crossclade neutralizing activity. Vaccine 25:5968-5977.
37. Buonaguro L, Monaco A, Arico E et al. (2008) Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. BMC Bioinformatics 9(Suppl 2):S5
38. Buonaguro L, Tornesello ML, Gallo RC et al. (2009a) Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles. J Virol 83:304-313.
39. Buonaguro L, Tornesello ML, Jewis GK et al. (2009b) Short communication: limited induction of IL-10 in PBMCs from HIV-infected subjects treated with HIV-VLPs. AIDS Res Hum Retroviruses 25:819-822.
40. Ceol A, Chatr AA, Licata L et al. (2010) MINT, the molecular interaction database: 2009 update. Nucleic Acids Res 38:D532-D539.
41. Chatr-Aryamontri A, Ceol A, Peluso D et al. (2009) VirusMINT: a viral protein interaction database. Nucleic Acids Res 37:D669-D673.
42. Chaussabel D, Quinn C, Shen J et al. (2008) A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29:150-164.
43. De Chassey B, Navratil V, Tafforeau L et al. (2008) Hepatitis C virus infection protein network. Mol Syst Biol 4:230
44. De La Torre MS, Torres C, Nieto G et al. (2008) Vitamin D receptor gene haplotypes and susceptibility to HIV-1 infection in injection drug users. J Infect Dis 197:405-410.
45. Den Dunnen J, Gringhuis SI, Geijtenbeek TB (2009) Innate signaling by the C-type lectin DC-SIGN dictates immune responses. Cancer Immunol Immunother 58:1149-1157.
46. Dhiman N, Ovsyannikova IG, Vierkant RA et al. (2008) Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine 26:1731-1736.
47. Dickinson AM and Holler E (2008) Polymorphisms of cytokine and innate immunity genes and GVHD. Best Pract Res Clin Haematol 21:149-164.
48. Didierlaurent A, Brissoni B, Velin D et al. (2006) Tollip regulates proinflammatory responses to interleukin-1 and lipopolysaccharide. Mol Cell Biol 26:735-742.
49. Diebold SS (2008) Recognition of viral single-stranded RNA by Toll-like receptors. Adv Drug Deliv Rev 60:813-823.
50. Diebold SS, Kaisho T, Hemmi H et al. (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:1529-1531.
51. Dillon S, Agrawal A, Van DT et al. (2004) A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J Immunol 172:4733-4743.
52. Dillon S, Agrawal S, Banerjee K et al. (2006) Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J Clin Invest 116:916-928.
53. Draper SJ and Heeney JL (2010) Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 8:62-73.
54. Driscoll T, Dyer MD, Murali TM et al. (2009) PIG-the pathogen interaction gateway. Nucleic Acids Res 37:D647-D650.
55. Elkon R, Linhart C, Halperin Y et al. (2007) Functional genomic delineation of TLR-induced transcriptional networks. BMC Genomics 8:394
56. Ferwerda B, McCall MB, Alonso S et al. (2007) TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci U S A 104:16645-16650.
57. Ferwerda B, McCall MB, Verheijen K et al. (2008) Functional consequences of toll-like receptor 4 polymorphisms. Mol Med 14:346-352.
58. Fraser CK, Diener KR, Brown MP et al. (2007) Improving vaccines by incorporating immunological coadjuvants. Expert Rev Vaccines 6:559-578.
59. Gallant S and Gilkeson G (2006) ETS transcription factors and regulation of immunity. Arch Immunol Ther Exp (Warsz) 54:149-163.
60. Gardy JL, Lynn DJ, Brinkman FS et al. (2009) Enabling a systems biology approach to immunology: focus on innate immunity. Trends Immunol 30:249-262.
61. Gaucher D, Therrien R, Kettaf N et al. (2008) Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205:3119-3131.
62. Geijtenbeek TB, Van Vliet SJ, Engering A et al. (2004) Self- and nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol 22:33-54.
63. Gelman AE, Zhang J, Choi Y et al. (2004) Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol 172:6065-6073.
64. Georgel P, Macquin C, Bahram S (2009) The heterogeneous allelic repertoire of human toll-like receptor (TLR) genes. PLoS One 4:e7803
65. Germain RN (2004) An innately interesting decade of research in immunology. Nat Med 10:1307-1320.
66. Gilliet M, Cao W, Liu YJ (2008) Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 8:594-606.
67. Gluck R, Moser C, Metcalfe IC (2004) Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Expert Opin Biol Ther 4:1139-1145.
68. Groux H, O'Garra A, Bigler M et al. (1997) A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389:737-742.
69. Hayashi F, Smith KD, Ozinsky A et al. (2001) The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410:1099-1103.
70. Heil F, Hemmi H, Hochrein H et al. (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303:1526-1529.
71. Hemmi H, Takeuchi O, Kawai T et al. (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408:740-745.
72. Hemmi H, Kaisho T, Takeuchi O et al. (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3:196-200.
73. Hemmi H, Kaisho T, Takeda K et al. (2003) The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J Immunol 170:3059-3064.
74. Heng TS and Painter MW (2008) The Immunological Genome Project: networks of gene expression in immune cells. Nat Immunol 9:1091-1094.
75. Hervas-Stubbs S, Olivier A, Boisgerault F et al. (2007) TLR3 ligand stimulates fully functional memory CD8+ T cells in the absence of CD4+ T-cell help. Blood 109:5318-5326.
76. Hijikata A, Kitamura H, Kimura Y et al. (2007) Construction of an open-access database that integrates cross-reference information from the transcriptome and proteome of immune cells. Bioinformatics 23:2934-2941.
77. Hoek KL, Carlesso G, Clark ES et al. (2009) Absence of mature peripheral B cell populations in mice with concomitant defects in B cell receptor and BAFF-R signaling. J Immunol 183:5630-5643.
78. Holzer BR, Hatz C, Schmidt-Sissolak D et al. (1996) Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine 14:982-986.
79. Houghton M and Abrignani S (2005) Prospects for a vaccine against the hepatitis C virus. Nature 436:961-966.
80. Hu J, Sealfon SC, Hayot F et al. (2007) Chromosome-specific and noisy IFNB1 transcription in individual virus-infected human primary dendritic cells. Nucleic Acids Res 35:5232-5241.
81. Huleatt JW, Nakaar V, Desai P et al. (2008) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26:201-214.
82. Inohara, Chamaillard, McDonald C et al. (2005) NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 74:355-383.
83. Ishii KJ and Akira S (2007) Toll or toll-free adjuvant path toward the optimal vaccine development. J Clin Immunol 27:363-371.
84. Janeway CA, Jr. and Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197-216.
85. Jenner RG and Young RA (2005) Insights into host responses against pathogens from transcriptional profiling. Nat Rev Microbiol 3:281-294.
86. Johnston D, Zaidi B, Bystryn JC (2007) TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines. Cancer Immunol Immunother 56:1133-1141.
87. Kaech SM, Wherry EJ, Ahmed R (2002) Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2:251-262.
88. Kang SM and Compans RW (2009) Host responses from innate to adaptive immunity after vaccination: molecular and cellular events. Mol Cells 27:5-14.
89. Kawabe T, Naka T, Yoshida K et al. (1994) The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1:167-178.
90. Keam SJ and Harper DM (2008) Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. Drugs 68:359-372.
91. Khan WN (2009) B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J Immunol 183:3561-3567.
92. Kimberlin DW and Whitley RJ (2007) Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med 356:1338-1343.
93. Kimman TG, Banus S, Reijmerink N et al. (2008) Association of interacting genes in the toll-like receptor signaling pathway and the antibody response to pertussis vaccination. PLoS One 3:e3665
94. Korb M, Rust AG, Thorsson V et al. (2008) The Innate Immune Database (IIDB). BMC Immunol 9:7
95. Korber BT, Letvin NL, Haynes BF (2009) T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol 83:8300-8314.
96. Kozlow EJ, Wilson GL, Fox CH et al. (1993) Subtractive cDNA cloning of a novel member of the Ig gene superfamily expressed at high levels in activated B lymphocytes. Blood 81:454-461.
97. Krieg AM (2006) Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5:471-484.
98. Krieg AM (2008) Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27:161-167.
99. Krishnan MN, Ng A, Sukumaran B et al. (2008) RNA interference screen for human genes associated with West Nile virus infection. Nature 455:242-245.
100. Kwissa M, Amara RR, Robinson HL et al. (2007a) Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J Exp Med 204:2733-2746.
101. Kwissa M, Kasturi SP, Pulendran B (2007b) The science of adjuvants. Expert Rev Vaccines 6:673-684.
102. Lafaille JJ (1998) The role of helper T cell subsets in autoimmune diseases. Cytokine Growth Factor Rev 9:139-151.
103. Lahiri A, Das P, Chakravortty D (2008) Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine 26:6777-6783.
104. Latz E, Franko J, Golenbock DT et al. (2004a) Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human tolllike receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity. J Immunol 172:2431-2438.
105. Latz E, Schoenemeyer A, Visintin A et al. (2004b) TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 5:190-198.
106. Leber JH, Crimmins GT, Raghavan S et al. (2008) Distinct TLR- and NLR-mediated transcriptional responses to an intracellular pathogen. PLoS Pathog 4:e6
107. Liu YJ (2005) IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23:275-306.
108. Longhi MP, Trumpfheller C, Idoyaga J et al. (2009) Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 206:1589-1602.
109. Lorenz E, Mira JP, Frees KL et al. (2002) Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 162:1028-1032.
110. Lund JM, Alexopoulou L, Sato A et al. (2004) Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 101:5598-5603.
111. Lynn DJ, Winsor GL, Chan C et al. (2008) InnateDB: facilitating systems-level analyses of the mammalian innate immune response. Mol Syst Biol 4:218
112. Ma R, Du JL, Huang J et al. (2007) Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination. Biochem Biophys Res Commun 361:537-542.
113. Magistrelli G, Jeannin P, Elson G et al. (1999) Identification of three alternatively spliced variants of human CD28 mRNA. Biochem Biophys Res Commun 259:34-37.
114. McCaffrey RL, Fawcett P, O'Riordan M et al. (2004) A specific gene expression program triggered by Gram-positive bacteria in the cytosol. Proc Natl Acad Sci U S A 101:11386-11391.
115. McGuirk P and Mills KH (2002) Pathogen-specific regulatory T cells provoke a shift in the Th1 Th2 paradigm in immunity to infectious diseases. Trends Immunol 23:450-455.
116. Mikszta JA, Dekker JP, III, Harvey NG et al. (2006) Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect Immun 74:6806-6810.
117. Misch EA and Hawn TR (2008) Toll-like receptor polymorphisms and susceptibility to human disease. Clin Sci (Lond) 114:347-360.
118. Miyairi I and De Vincenzo JP (2008) Human genetic factors and respiratory syncytial virus disease severity. Clin Microbiol Rev 21:686-703.
119. Monaco A, Marincola FM, Sabatino M et al. (2009) Molecular immune signatures of HIV-1 vaccines in human PBMCs. FEBS Lett 583:3004-3008.
120. Monath TP (2005) Yellow fever vaccine. Expert Rev Vaccines 4:553-574.
121. Monie TP, Bryant CE, Gay NJ (2009) Activating immunity: lessons from the TLRs and NLRs. Trends Biochem Sci 34:553-561.
122. Moser M and Murphy KM (2000) Dendritic cell regulation of TH1-TH2 development. Nat Immunol 1:199-205.
123. Mowen KA and Glimcher LH (2004) Signaling pathways in Th2 development. Immunol Rev 202:203-222.
124. Navabi H, Jasani B, Reece A et al. (2009) A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 27:107-115.
125. Navratil V, De CB, Meyniel L et al. (2009) VirHostNet: a knowledge base for the management and the analysis of proteome-wide virus-host interaction networks. Nucleic Acids Res 37:D661-D668.
126. Nguyen TH, Mai NL, Le TP et al. (2009) Toll-like receptor 4 (TLR4) and typhoid fever in Vietnam. PLoS One 4:e4800.
127. O'Garra A and Robinson D (2004) Development and function of T helper 1 cells. Adv Immunol 83:133-162.
128. O'Garra A and Vieira P (2004) Regulatory T cells and mechanisms of immune system control. Nat Med 10:801-805.
129. Oda K and Kitano H (2006) A comprehensive map of the toll-like receptor signaling network. Mol Syst Biol 2:2006.
130. Ogus AC, Yoldas B, Ozdemir T et al. (2004) The Arg753GLn polymorphism of the human tolllike receptor 2 gene in tuberculosis disease. Eur Respir J 23:219-223.
131. Ott G, Barchfeld GL, Chernoff D et al. (1995) MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol 6:277-296.
132. Ovsyannikova IG, Dhiman N, Haralambieva IH et al. (2010) Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes. Hum Genet 127:207-221.
133. Ozinsky A, Underhill DM, Fontenot JD et al. (2000) The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci U S A 97:13766-13771.
134. Pancharoen C, Mekmullica J, Thisyakorn U et al. (2005) Reduced-dose intradermal vaccination against hepatitis A with an aluminum-free vaccine is immunogenic and can lower costs. Clin Infect Dis 41:1537-1540.
135. Pasare C and Medzhitov R (2005) Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol 560:11-18.
136. Pashine A, Valiante NM, Ulmer JB (2005) Targeting the innate immune response with improved vaccine adjuvants. Nat Med 11:S63-S68.
137. Pine SO, McElrath MJ, Bochud PY (2009) Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals. AIDS 23:2387-2395.
138. Pitti RM, Marsters SA, Lawrence DA et al. (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396:699-703.
139. Plotkin SA (2005) Vaccines: past, present and future. Nat Med 11:S5-S11.
140. Poltorak A, He X, Smirnova I et al. (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085-2088.
141. Potti A, Dressman HK, Bild A et al. (2006) Genomic signatures to guide the use of chemotherapeutics. Nat Med 12:1294-1300.
142. Pulendran B and Ahmed R (2006) Translating innate immunity into immunological memory: implications for vaccine development. Cell 124:849-863.
143. Querec T, Bennouna S, Alkan S et al. (2006) Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203:413-424.
144. Querec TD, Akondy RS, Lee EK et al. (2009) Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10:116-125.
145. Ramilo O, Allman W, Chung W et al. (2007) Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood 109:2066-2077.
146. Rappuoli R (2004) From Pasteur to genomics: progress and challenges in infectious diseases. Nat Med 10:1177-1185.
147. Rappuoli R (2007) Bridging the knowledge gaps in vaccine design. Nat Biotechnol 25:1361-1366.
148. Read RC, Pullin J, Gregory S et al. (2001) A functional polymorphism of toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease. J Infect Dis 184:640-642.
149. Redecke V, Hacker H, Datta SK et al. (2004) Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J Immunol 172:2739-2743.
150. Reed SG, Bertholet S, Coler RN et al. (2009) New horizons in adjuvants for vaccine development. Trends Immunol 30:23-32.
151. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. (2009) Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med 361:2209-2220.
152. Rezazadeh M, Hajilooi M, Rafiei A et al. (2006) TLR4 polymorphism in Iranian patients with brucellosis. J Infect 53:206-210.
153. Ricciardi-Castagnoli P and Granucci F (2002) Opinion: Interpretation of the complexity of innate immune responses by functional genomics. Nat Rev Immunol 2:881-889.
154. Richter JD and Sonenberg N (2005) Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 433:477-480.
155. Robbins JB, Schneerson R, Szu SC (1995) Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 171:1387-1398.
156. Robbins JB, Schneerson R, Szu SC (1996) Hypothesis: how licensed vaccines confer protective immunity. Adv Exp Med Biol 397:169-182.
157. Ron D and Walter P (2007) Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8:519-529.
158. Ryan ET and Calderwood SB (2000) Cholera vaccines. Clin Infect Dis 31:561-565.
159. Sallberg M, Frelin L, Weiland O (2009) DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target. Expert Opin Biol Ther 9:805-815.
160. Santos AP, Matos DC, Bertho AL et al. (2008) Detection of Th1/Th2 cytokine signatures in yellow fever 17DD first-time vaccinees through ELISpot assay. Cytokine 42:152-155.
161. Sato Y, Goto Y, Narita N et al. (2009) Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. Cancer Microenviron 2(Suppl 1):205-214.
162. Schmidt WM, Spiel AO, Jilma B et al. (2009) In vivo profile of the human leukocyte microRNA response to endotoxemia. Biochem Biophys Res Commun 380:437-441.
163. Schonbeck U and Libby P (2001) The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 58:4-43.
164. Schroder NW and Schumann RR (2005) Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 5:156-164.
165. Shimazu R, Akashi S, Ogata H et al. (1999) MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 189:1777-1782.
166. Sioud M (2009) Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines? Scand J Immunol 70:516-525.
167. Smirnova I, Mann N, Dols A et al. (2003) Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. Proc Natl Acad Sci U S A 100:6075-6080.
168. Sorlie T, Perou CM, Tibshirani R et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874.
169. Speiser DE, Lienard D, Rufer N et al. (2005) Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115:739-746.
170. Stahl S, Fung E, Adams C et al. (2009) Proteomics and pathway analysis identifies JNK signaling as critical for high linear energy transfer radiation-induced apoptosis in non-small lung cancer cells. Mol Cell Proteomics 8:1117-1129.
171. Stephan MT, Ponomarev V, Brentjens RJ et al. (2007) T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 13:1440-1449.
172. Sun HJ, Xu X, Wang XL et al. (2006) Transcription factors Ets2 and Sp1 act synergistically with histone acetyltransferase p300 in activating human interleukin-12 p40 promoter. Acta Biochim Biophys Sin (Shanghai) 38:194-200.
173. Takeda K and Akira S (2007) Toll-like receptors. Curr Protoc Immunol Chapter 14: Unit PMID: 18432983 DOI: 10.1002/0471142735.im1412s77.
174. Takeda K, Kaisho T, Akira S (2003) Toll-like receptors. Annu Rev Immunol 21:335-376.
175. Takeuchi O, Kawai T, Muhlradt PF et al. (2001) Discrimination of bacterial lipoproteins by Tolllike receptor 6. Int Immunol 13:933-940.
176. Takeuchi O, Sato S, Horiuchi T et al. (2002) Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 169:10-14.
177. Tanabe M, Kurita-Taniguchi M, Takeuchi K et al. (2003) Mechanism of up-regulation of human Toll-like receptor 3 secondary to infection of measles virus-attenuated strains. Biochem Biophys Res Commun 311:39-48.
178. Thomas V and Fikrig E (2002) The Lyme disease vaccine takes its toll. Vector Borne Zoonotic Dis 2:217-222.
179. Tong NK, Beran J, Kee SA et al. (2005) Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 68:2298-2303.
180. Tsuji S, Matsumoto M, Takeuchi O et al. (2000) Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors. Infect Immun 68:6883-6890.
181. Uehori J, Matsumoto M, Tsuji S et al. (2003) Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guerin peptidoglycan. Infect Immun 71:4238-4249.
182. Van Manen D, Rits MA, Beugeling C et al. (2008) The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog 4:e18.
183. Van DP, Oosterhuis-Kafeja F, Van Der WM et al. (2009) Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 27:454-459.
184. Vasilescu C, Rossi S, Shimizu M et al. (2009) MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PLoS One 4:e7405
185. Velez DR, Wejse C, Stryjewski ME et al. (2010) Variants in toll-like receptors 2 and 9 influence susceptibility to pulmonary tuberculosis in Caucasians, African-Americans, and West Africans. Hum Genet 127:65-73.
186. Villadangos JA and Young L (2008) Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 29:352-361.
187. Von Andrian UH and Mempel TR (2003) Homing and cellular traffic in lymph nodes. Nat Rev Immunol 3:867-878.
188. Wang Z, Gerstein M, Snyder M (2009) RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10:57-63.
189. Wille-Reece U, Flynn BJ, Lore K et al. (2006) Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 203:1249-1258.
190. Wurfel MM, Gordon AC, Holden TD et al. (2008) Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am J Respir Crit Care Med 178:710-720.
191. Yim JJ, Lee HW, Lee HS et al. (2006) The association between microsatellite polymorphisms in intron II of the human Toll-like receptor 2 gene and tuberculosis among Koreans. Genes Immun 7:150-155.
192. Yin JQ, Zhao RC, Morris KV (2008) Profiling microRNA expression with microarrays. Trends Biotechnol 26:70-76.
193. Yoneyama M and Fujita T (2009) RNA recognition and signal transduction by RIG-I-like receptors. Immunol Rev 227:54-65.
194. Yoneyama M, Kikuchi M, Natsukawa T et al. (2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5:730-737.
195. Yoneyama M, Kikuchi M, Matsumoto K et al. (2005) Shared and unique functions of the DExD H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 175:2851-2858.
196. Yoshida A, Inagawa H, Kohchi C et al. (2009) The role of toll-like receptor 2 in survival strategies of Mycobacterium tuberculosis in macrophage phagosomes. Anticancer Res 29:907-910.
197. Zhou R, Hu G, Liu J et al. (2009) NF-kappaB p65-dependent transactivation of miRNA genes following Cryptosporidium parvum infection stimulates epithelial cell immune responses. PLoS Pathog 5:e1000681.